Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Ekso Bionics Holdings (EKSO) over the last 14 years, with Q3 2025 value amounting to -$38000.0.

  • Ekso Bionics Holdings' Change in Accured Expenses rose 7777.78% to -$38000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$501000.0, marking a year-over-year decrease of 797.41%. This contributed to the annual value of -$599000.0 for FY2024, which is 34701.49% down from last year.
  • Latest data reveals that Ekso Bionics Holdings reported Change in Accured Expenses of -$38000.0 as of Q3 2025, which was up 7777.78% from -$518000.0 recorded in Q2 2025.
  • In the past 5 years, Ekso Bionics Holdings' Change in Accured Expenses registered a high of $568000.0 during Q3 2022, and its lowest value of -$723000.0 during Q1 2024.
  • Moreover, its 5-year median value for Change in Accured Expenses was -$38000.0 (2025), whereas its average is -$68684.2.
  • In the last 5 years, Ekso Bionics Holdings' Change in Accured Expenses tumbled by 325000.0% in 2022 and then surged by 43150.68% in 2023.
  • Quarter analysis of 5 years shows Ekso Bionics Holdings' Change in Accured Expenses stood at $449000.0 in 2021, then plummeted by 83.74% to $73000.0 in 2022, then skyrocketed by 431.51% to $388000.0 in 2023, then plummeted by 34.79% to $253000.0 in 2024, then plummeted by 115.02% to -$38000.0 in 2025.
  • Its Change in Accured Expenses was -$38000.0 in Q3 2025, compared to -$518000.0 in Q2 2025 and -$198000.0 in Q1 2025.